EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer

Pancreas

Volumn 41, Issue 3, 2012, Pages 428-434

  Oliveira Cunha, Melissa ^a   Hadfield, Kristen D ^b   Siriwardena, Ajith K ^a   Newman, William ^b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

EGFR; KRAS; mutations in EGFR; pancreas cancer; survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CODON; CONTROLLED STUDY; DNA SEQUENCE; DUODENUM CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PANCREAS BIOPSY; PANCREAS CANCER; PANCREATICODUODENECTOMY; PERIAMPULLARY CANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CODON; DIGESTIVE SYSTEM NEOPLASMS; DNA MUTATIONAL ANALYSIS; ENGLAND; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PHENOTYPE; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859098811     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182327a03     Document Type: Article

References (62)

1. Friess H, Kleeff J, Korc M, Buchler MW. Molecular aspects of pancreatic cancer and future perspectives. Dig Surg. 1999;16(4):281-290. (Pubitemid 29376329)
2. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33(4):369-385. (Pubitemid 44142736)
3. Iyer R, Thames HD, Tealer JR, et al. Effect of reduced EGFR function on the radiosensitivity and proliferative capacity of mouse jejunal crypt clonogens. Radiother Oncol. 2004;72(3):283-289. (Pubitemid 39265381)
4. Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A. 1986;83(14):5141-5144. (Pubitemid 16051332)
5. Shimizu N, Kondo H, Gamou MA, et al. Genetic analysis of hyper production of epidermal growth factor receptors in human epidermoid carcinoma A431 cells. Somatic Cell Mol Genet. 1984;10:45-53. (Pubitemid 14115526)
6. Lee J, Jang KT, Ki CS, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007;109(8):1561-1569. (Pubitemid 46595692)
7. Kwak EL, Jankowski J, Thayer SP, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006;12(14 pt 1):4283-4287.
8. Choi JE, Park SH, Kim KM, et al. Polymorphisms inthe epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study. BMC Cancer. 2007;7:199.
9. Ma F, Sun T, Shi Y, et al. Polymorphisms of eGFR predict clinical outcome in advanced nonYsmall-cell lung cancer patients treated with gefitinib. Lung Cancer. 2009;66(1):114-119.
10. Blons H, Pallier K, Le Corre D, et al. Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC Med Genomics. 2008;1:25.
11. Kaneko K, Kumekawa Y, Makino R, et al. EGFR gene alterations asa prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci. 2010;15:65-72.
12. Watanabe M, Nobuta A, Tanaka J, et al. An effect of k-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int J Cancer. 1996;67(2):264-268. (Pubitemid 26274159)
13. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations innonYsmall-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23(4):857-865. (Pubitemid 46224186)
14. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancerVmolecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133-144.
15. Salto-Tellez M. Molecular cytopathology and personalised medicine. Cytology 2010. Edinburgh. Available at: http://www.cytology2010.com/UserFiles/ File/Manuel%20Salto-Tellez%20Edinburgh%202010%20lecture%20notes.pdf. Accessed February 23, 2011.
16. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005;102(21):7665-7670.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations inthe epidermal growth factor receptor underlying responsiveness of nonYsmall-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. (Pubitemid 38637993)
18. Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005;65(16):7096-7101. (Pubitemid 41161238)
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-1500. (Pubitemid 38720929)
20. Wang WS, Chen PM, Chiou TJ, et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res. 2007;13(12):3597-3604.
21. Zhang W, Stoehlmacher J, Park DJ, et al. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2005;5(2):124-131.
22. Dong M, Nio Y, Guo KJ, et al. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. 1998;18(6B):4613-4619. (Pubitemid 29042032)
23. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13(3):565-569.
24. Mimori K, Nagahara H, Barnard GF, et al. Epidermal growth factor receptor gene is highly conserved in pancreatic cancer cells. Pancreas. 2005;31(3):299. (Pubitemid 41400496)
25. Tzeng CW, Frolov A, Frolova N, et al. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery. 2007;141(4):464-469. (Pubitemid 46441307)
26. Immervoll H, Hoem D, Kugarajh K, et al. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006;448(6):788-796. (Pubitemid 43824436)
27. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958-967.
28. Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2009;126(3):651-655.
29. Kosaka T, Yatabe Y, Onozato R, et al. Prognostic implication of eGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009;4(1):22-29.
30. Nagahara H, Mimori K, Ohta M, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res. 2005;11(4):1368-1371. (Pubitemid 40315215)
31. Hama T, Yuza Y, Saito Y, et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist. 2009;14(9):900-908.
32. Sholl LM, Yeap BY, Iafrate AJ, et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res. 2009;69(21):8341-8348.
33. Gazdar AF. Activating and resistance mutations of EGFR in nonYsmall-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(suppl 1):S24-S31.
34. Kokubo Y, Gemma A, Noro R, et al. Reduction of pTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer. 2005;92(9):1711-1719. (Pubitemid 40756483)
35. Giaccone G, Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat Clin Pract Oncol. 2005;2(11):554-561. (Pubitemid 41721815)
36. Van Damme N, Deron P, Van Roy N, et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer. 2010;10:189.
37. Tomizawa Y, Iijima H, Sunaga N, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with nonYsmall cell lung cancer. Clin Cancer Res. 2005;11(19 pt 1):6816-6822. (Pubitemid 41428736)
38. Soung YH, Lee JW, Kim SY, et al. Mutational analysis of eGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch. 2005;446(5):483-488.
39. Bae NC, Chae MH, Lee MH, et al. EGFR, ERBB2, and KRAS mutations in Korean nonYsmall cell lung cancer patients. Cancer Genet Cytogenet. 2007;173(2):107-113. (Pubitemid 46281348)
40. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53(4):549-554.
41. Apple SK, Hecht JR, Lewin DN, et al. Immunohistochemical evaluation of k-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol. 1999;30(2):123-129. (Pubitemid 29086941)
42. Berndt C, Haubold K, Wenger F, et al. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem. 1998;44(10):2103-2107. (Pubitemid 28447056)
43. Caldas C, Hahn SA, Hruban RH, et al. Detection of k-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994;54(13):3568-3573. (Pubitemid 24225985)
44. Capella G, Cronauer-Mitra S, Pienado MA, et al. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect. 1991;93:125-131.
45. Dergham ST, Dugan MC, Kucway R, et al. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol. 1997;21(2):127-143. (Pubitemid 27278611)
46. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143(2):545-554. (Pubitemid 24058210)
47. Hsiang D, Friess H, Buchler MW, et al. Absence of k-ras mutations in the pancreatic parenchyma of patients with chronic pancreatitis. Am J Surg. 1997;174(3):242-246. (Pubitemid 27415347)
48. Kawesha A, Ghaneh P, Andren-Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2000;89(6):469-474.
49. Rivera JA, Rall CJ, Graeme-Cook F, et al. Analysis of k-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. Surgery. 1997;121(1):42-49. (Pubitemid 27043743)
50. Smit VT, Boot AJ, Smits AM, et al. KRAS codon 12mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988;16(16):7773-7782.
51. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al. Clinical significance of k-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis. Int J Gastrointest Cancer. 2005;35(1):33-41. (Pubitemid 40458578)
52. Terhune PG, Phifer DM, Tosteson TD, et al. K-ras mutation infocal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev. 1998;7(6):515-521. (Pubitemid 28354115)
53. Wenger FA, Zieren J, Peter FJ, et al. K-ras mutations intissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. Langenbecks Arch Surg. 1999;384(2):181-186. (Pubitemid 29227310)
54. Zinsky R, Bolukbas S, Bartsch H, et al. Analysis of KRAS mutations of exon 2 codons 12 and 13 by SNaPshot analysis in comparison to common DNA sequencing. Gastroenterol Res Pract. 2010;2010:789363.
55. Schultz NA, Roslind A, Christensen IJ, et al. KRAS mutations and relation to prognosis in patients operated for localized pancreatic cancer and other periampullary cancers. J Clin Oncol (Meeting Abstracts). 2009;27(15S):e15618.
56. Scarpa A, Capelli P, Villaneuva A, et al. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int J Cancer. 1994;57(2):167-171. (Pubitemid 24144203)
57. Wei S, Liang Z, Gao J, et al. Patterns of k-ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing. J Gastroenterol Hepatol. 2005;20(1):67-72. (Pubitemid 40143636)
58. Motojima K, Urano T, Nagata Y, et al. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann Surg. 1993;217(2):138-143. (Pubitemid 23059284)
59. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6(8):2969-2972. (Pubitemid 30637716)
60. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-1765.
61. da Cunha Santos G, Dhani N, Tu D, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer. 2010;116(24):5599-5607.
62. Boeck SH, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): a randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). ASCO Annual Meeting Proceedings. Vol. 28. Chicago, IL. J Clin Oncol. 2010;28(suppl):18s. Abstrct LBA4011.